| Literature DB >> 27330053 |
Philip M Grant1, Douglas Kitch2, Grace A McComsey3, Ann C Collier4, Susan L Koletar5, Kristine M Erlandson6, Michael T Yin7, Benedetta Bartali8, Belinda Ha9, Kathy Melbourne10, Todd T Brown11.
Abstract
We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.Entities:
Keywords: HIV infections, drug therapy/virology; anti-HIV agents, administration and dosage, adverse effects; bone density
Mesh：
Substances：
Year: 2016 PMID： 27330053 PMCID： PMC4957444 DOI： 10.1093/infdis/jiw204
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226